Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo.

Biscans A, Coles A, Haraszti R, Echeverria D, Hassler M, Osborn M, Khvorova A.

Nucleic Acids Res. 2018 Dec 14. doi: 10.1093/nar/gky1239. [Epub ahead of print]

PMID:
30544191
2.

Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial.

Ambrosy AP, Lewis GD, Malhotra R, Jones AD, Greene SJ, Fudim M, Coles A, Butler J, Sharma A, Hernandez AF, Mentz RJ.

J Cardiovasc Med (Hagerstown). 2018 Dec 3. doi: 10.2459/JCM.0000000000000736. [Epub ahead of print] No abstract available.

PMID:
30540649
3.

Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways.

Osborn MF, Coles AH, Biscans A, Haraszti RA, Roux L, Davis S, Ly S, Echeverria D, Hassler MR, Godinho BMDC, Nikan M, Khvorova A.

Nucleic Acids Res. 2018 Dec 8. doi: 10.1093/nar/gky1232. [Epub ahead of print]

PMID:
30535404
4.

Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial.

Pagidipati NJ, Coles A, Hemal K, Lee KL, Dolor RJ, Pellikka PA, Mark DB, Patel MR, Litwin SE, Daubert MA, Shah SH, Hoffmann U, Douglas PS; PROMISE Investigators.

Am Heart J. 2018 Nov 9;208:28-36. doi: 10.1016/j.ahj.2018.11.002. [Epub ahead of print]

PMID:
30529930
5.

Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series.

Roos JCP, Moran C, Chatterjee VK, Jones J, Coles A, Murthy R.

Eye (Lond). 2018 Nov 29. doi: 10.1038/s41433-018-0282-1. [Epub ahead of print]

PMID:
30498266
6.

RNAi modulation of placental sFLT1 for the treatment of preeclampsia.

Turanov AA, Lo A, Hassler MR, Makris A, Ashar-Patel A, Alterman JF, Coles AH, Haraszti RA, Roux L, Godinho BMDC, Echeverria D, Pears S, Iliopoulos J, Shanmugalingam R, Ogle R, Zsengeller ZK, Hennessy A, Karumanchi SA, Moore MJ, Khvorova A.

Nat Biotechnol. 2018 Nov 19. doi: 10.1038/nbt.4297. [Epub ahead of print]

PMID:
30451990
7.

Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points.

Greene SJ, Hernandez AF, Sun JL, Butler J, Armstrong PW, Ezekowitz JA, Zannad F, Ferreira JP, Coles A, Metra M, Voors AA, Califf RM, O'Connor CM, Mentz RJ.

Circ Cardiovasc Qual Outcomes. 2018 Oct;11(10):e004783. doi: 10.1161/CIRCOUTCOMES.118.004783.

PMID:
30354576
8.

Exosomes Produced from 3D Cultures of MSCs by Tangential Flow Filtration Show Higher Yield and Improved Activity.

Haraszti RA, Miller R, Stoppato M, Sere YY, Coles A, Didiot MC, Wollacott R, Sapp E, Dubuke ML, Li X, Shaffer SA, DiFiglia M, Wang Y, Aronin N, Khvorova A.

Mol Ther. 2018 Dec 5;26(12):2838-2847. doi: 10.1016/j.ymthe.2018.09.015. Epub 2018 Sep 22.

9.

Sarcoidosis following alemtuzumab treatment for multiple sclerosis.

Willis MD, Hope-Gill B, Flood-Page P, Joseph F, Needham E, Jones J, Coles A, Robertson NP.

Mult Scler. 2018 Nov;24(13):1779-1782. doi: 10.1177/1352458518790391. Epub 2018 Oct 11.

PMID:
30307364
10.

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.

Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, Hartung HP, Selmaj KW, Weiner HL, Daizadeh N, Margolin DH, Chirieac MC, Compston DAS.

Mult Scler. 2018 Oct 5:1352458518796675. doi: 10.1177/1352458518796675. [Epub ahead of print]

PMID:
30289355
11.

Renal Function and Exercise Training in AmbulatoryHeart Failure Patients With a Reduced Ejection Fraction.

Ambrosy AP, Mulder H, Coles A, Krauss WE, Lam CSP, McCullough PA, Pina I, Tromp J, Whellan DJ, O'Connor CM, Mentz RJ.

Am J Cardiol. 2018 Sep 15;122(6):999-1007. doi: 10.1016/j.amjcard.2018.06.011. Epub 2018 Jun 23.

PMID:
30269900
12.

Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation.

Khandaker GM, Oltean BP, Kaser M, Dibben CRM, Ramana R, Jadon DR, Dantzer R, Coles AJ, Lewis G, Jones PB.

BMJ Open. 2018 Sep 21;8(9):e025333. doi: 10.1136/bmjopen-2018-025333.

13.

Author response: Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles AJ.

Neurology. 2018 Sep 18;91(12):581-582. doi: 10.1212/WNL.0000000000006203. No abstract available.

PMID:
30224508
14.

Comparison of International Guidelines for Assessment of Suspected Stable Angina: Insights From the PROMISE and SCOT-HEART.

Adamson PD, Newby DE, Hill CL, Coles A, Douglas PS, Fordyce CB.

JACC Cardiovasc Imaging. 2018 Sep;11(9):1301-1310. doi: 10.1016/j.jcmg.2018.06.021.

15.

Nuclear Localization of Huntingtin mRNA Is Specific to Cells of Neuronal Origin.

Didiot MC, Ferguson CM, Ly S, Coles AH, Smith AO, Bicknell AA, Hall LM, Sapp E, Echeverria D, Pai AA, DiFiglia M, Moore MJ, Hayward LJ, Aronin N, Khvorova A.

Cell Rep. 2018 Sep 4;24(10):2553-2560.e5. doi: 10.1016/j.celrep.2018.07.106.

16.

Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION.

Luo N, O'Connor CM, Cooper LB, Sun JL, Coles A, Reed SD, Whellan DJ, Piña IL, Kraus WE, Mentz RJ.

Eur J Heart Fail. 2018 Aug 31. doi: 10.1002/ejhf.1299. [Epub ahead of print]

PMID:
30168635
17.

Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled study.

Ellis J, van Maurik A, Fortunato L, Gisbert S, Chen K, Schwartz A, McHugh S, Want A, Santos Franco S, Oliveira JJ, Price J, Coles A, Brown K, Su D, Craigen JL, Yang J, Brett S, Davis B, Cheriyan J, Kousin-Ezewu O, Gray F, Thompson PW, Fernando D.

Br J Clin Pharmacol. 2018 Aug 30. doi: 10.1111/bcp.13748. [Epub ahead of print]

PMID:
30161291
18.

Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION.

Fudim M, O'Connor CM, Mulder H, Coles A, Bhatt AS, Ambrosy AP, Kraus WE, Piña IL, Whellan DJ, Mentz RJ.

Am Heart J. 2018 Nov;205:133-141. doi: 10.1016/j.ahj.2018.06.017. Epub 2018 Jul 29.

PMID:
30158057
19.

Transvascular Delivery of Hydrophobically Modified siRNAs: Gene Silencing in the Rat Brain upon Disruption of the Blood-Brain Barrier.

Godinho BMDC, Henninger N, Bouley J, Alterman JF, Haraszti RA, Gilbert JW, Sapp E, Coles AH, Biscans A, Nikan M, Echeverria D, DiFiglia M, Aronin N, Khvorova A.

Mol Ther. 2018 Nov 7;26(11):2580-2591. doi: 10.1016/j.ymthe.2018.08.005. Epub 2018 Aug 8.

PMID:
30143435
20.

Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial.

Fudim M, Loungani R, Doerfler SM, Coles A, Greene SJ, Cooper LB, Fiuzat M, O'Connor CM, Rogers JG, Mentz RJ.

Am Heart J. 2018 Oct;204:163-173. doi: 10.1016/j.ahj.2018.07.019. Epub 2018 Jul 29.

PMID:
30121018
21.

Women on multiple sclerosis clinical trial steering committees.

Moneim J, Coles A, Giovannoni G, Horne R, Carr O.

Ann Neurol. 2018 Aug;84(2):329-330. doi: 10.1002/ana.25306. Epub 2018 Sep 9. No abstract available.

PMID:
30063257
22.

Plasma cell depletion with bortezomib in the treatment of refractory N-methyl-d-aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment.

Keddie S, Crisp SJ, Blackaby J, Cox A, Coles A, Hart M, Church AJ, Vincent A, Zandi M, Lunn MP.

Eur J Neurol. 2018 Nov;25(11):1384-1388. doi: 10.1111/ene.13759. Epub 2018 Aug 31.

PMID:
30035842
23.

Differences Between Patients Enrolled Early and Late During Clinical Trial Recruitment: Insights From the HF-ACTION Trial.

Warraich HJ, O'Connor C, Wu A, Coles A, Kraus WE, Piña IL, Whellan DJ, Mentz RJ.

Circ Cardiovasc Qual Outcomes. 2018 Jul;11(7):e004643. doi: 10.1161/CIRCOUTCOMES.117.004643. No abstract available.

PMID:
29980656
24.

Study of immunotherapy in antibody positive psychosis: feasibility and acceptability (SINAPPS1).

Lennox BR, Tomei G, Vincent SA, Yeeles K, Pollard R, Palmer-Cooper E, Jones P, Zandi MS, Coles A.

J Neurol Neurosurg Psychiatry. 2018 Jun 11. pii: jnnp-2018-318124. doi: 10.1136/jnnp-2018-318124. [Epub ahead of print] No abstract available.

PMID:
29891740
25.

Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features.

Pariani N, Willis M, Muller I, Healy S, Nasser T, McGowan A, Lyons G, Jones J, Chatterjee K, Dayan C, Robertson N, Coles A, Moran C.

J Clin Endocrinol Metab. 2018 Aug 1;103(8):3010-3018. doi: 10.1210/jc.2018-00359.

26.

Efficient Gene Silencing in Brain Tumors with Hydrophobically Modified siRNAs.

Osborn MF, Coles AH, Golebiowski D, Echeverria D, Moazami MP, Watts JK, Sena-Esteves M, Khvorova A.

Mol Cancer Ther. 2018 Jun;17(6):1251-1258. doi: 10.1158/1535-7163.MCT-17-1144. Epub 2018 Apr 13.

PMID:
29654062
27.

Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.

Saarela M, Senthil K, Jones J, Tienari PJ, Soilu-Hänninen M, Airas L, Coles A, Saarinen JT.

Neurology. 2018 May 1;90(18):849-851. doi: 10.1212/WNL.0000000000005420. Epub 2018 Mar 30. No abstract available.

PMID:
29602914
28.

Imaging intralesional heterogeneity of sodium concentration in multiple sclerosis: Initial evidence from 23Na-MRI.

Grist JT, Riemer F, McLean MA, Matys T, Zaccagna F, Hilborne SF, Mason JP, Patterson I, Slough R, Kaggie J, Deen SS, Graves MJ, Jones JL, Coles AJ, Gallagher FA.

J Neurol Sci. 2018 Apr 15;387:111-114. doi: 10.1016/j.jns.2018.01.027. Epub 2018 Feb 6.

29.

High-Sensitivity Troponin I and Coronary Computed Tomography in Symptomatic Outpatients With Suspected Coronary Artery Disease: Insights From the PROMISE Trial.

Januzzi JL Jr, Suchindran S, Coles A, Ferencik M, Patel MR, Hoffmann U, Ginsburg GS, Douglas PS; PROMISE Investigators.

JACC Cardiovasc Imaging. 2018 Mar 14. pii: S1936-878X(18)30132-3. doi: 10.1016/j.jcmg.2018.01.021. [Epub ahead of print]

PMID:
29550314
30.

Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial.

Cerbin LP, Ambrosy AP, Greene SJ, Armstrong PW, Butler J, Coles A, DeVore AD, Ezekowitz JA, Hernandez AF, Metra M, Starling RC, Tang W, Teerlink JR, Voors AA, Wu A, O'Connor CM, Mentz RJ.

JACC Heart Fail. 2018 Apr;6(4):298-307. doi: 10.1016/j.jchf.2018.01.018. Epub 2018 Mar 7.

PMID:
29525328
31.

Authorship of phase 3 trials in multiple sclerosis.

Coles A.

Ann Neurol. 2018 Apr;83(4):653-655. doi: 10.1002/ana.25203. No abstract available.

PMID:
29518276
32.

Alemtuzumab as Treatment for Multiple Sclerosis.

Katsavos S, Coles A.

Cold Spring Harb Perspect Med. 2018 Oct 1;8(10). pii: a032029. doi: 10.1101/cshperspect.a032029. Review.

PMID:
29500306
33.

A review of brain stimulation methods to treat substance use disorders.

Coles AS, Kozak K, George TP.

Am J Addict. 2018 Mar;27(2):71-91. doi: 10.1111/ajad.12674. Epub 2018 Feb 19. Review.

34.

Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo.

Hassler MR, Turanov AA, Alterman JF, Haraszti RA, Coles AH, Osborn MF, Echeverria D, Nikan M, Salomon WE, Roux L, Godinho BMDC, Davis SM, Morrissey DV, Zamore PD, Karumanchi SA, Moore MJ, Aronin N, Khvorova A.

Nucleic Acids Res. 2018 Mar 16;46(5):2185-2196. doi: 10.1093/nar/gky037.

35.

Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).

Bhatt AS, Cooper LB, Ambrosy AP, Clare RM, Coles A, Joyce E, Krishnamoorthy A, Butler J, Felker GM, Ezekowitz JA, Armstrong PW, Hernandez AF, O'Connor CM, Mentz RJ.

J Am Heart Assoc. 2018 Feb 3;7(3). pii: e006740. doi: 10.1161/JAHA.117.006740.

36.

Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells.

Smets I, Fiddes B, Garcia-Perez JE, He D, Mallants K, Liao W, Dooley J, Wang G, Humblet-Baron S, Dubois B, Compston A, Jones J, Coles A, Liston A, Ban M, Goris A, Sawcer S.

Brain. 2018 Jan 18. doi: 10.1093/brain/awx372. [Epub ahead of print]

37.

Impact of Diabetes Mellitus on the Evaluation of Stable Chest Pain Patients: Insights From the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) Trial.

Sharma A, Sekaran NK, Coles A, Pagidipati NJ, Hoffmann U, Mark DB, Lee KL, Al-Khalidi HR, Lu MT, Pellikka PA, Trong QA, Douglas PS.

J Am Heart Assoc. 2017 Oct 31;6(11). pii: e007019. doi: 10.1161/JAHA.117.007019. Erratum in: J Am Heart Assoc. 2017 Dec 2;6(12):e004218.

38.

Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF.

Fudim M, O'Connor CM, Dunning A, Ambrosy AP, Armstrong PW, Coles A, Ezekowitz JA, Greene SJ, Metra M, Starling RC, Voors AA, Hernandez AF, Michael Felker G, Mentz RJ.

Eur J Heart Fail. 2018 Feb;20(2):304-314. doi: 10.1002/ejhf.1020. Epub 2017 Oct 29.

PMID:
29082629
39.

Pharmacokinetic Profiling of Conjugated Therapeutic Oligonucleotides: A High-Throughput Method Based Upon Serial Blood Microsampling Coupled to Peptide Nucleic Acid Hybridization Assay.

Godinho BMDC, Gilbert JW, Haraszti RA, Coles AH, Biscans A, Roux L, Nikan M, Echeverria D, Hassler M, Khvorova A.

Nucleic Acid Ther. 2017 Dec;27(6):323-334. doi: 10.1089/nat.2017.0690. Epub 2017 Oct 12.

40.

A High-throughput Assay for mRNA Silencing in Primary Cortical Neurons in vitro with Oligonucleotide Therapeutics.

Alterman JF, Coles AH, Hall LM, Aronin N, Khvorova A, Didiot MC.

Bio Protoc. 2017 Aug 20;7(16). pii: e2501. doi: 10.21769/BioProtoc.2501.

41.

Quantifying sociodemographic and income disparities in medical therapy and lifestyle among symptomatic patients with suspected coronary artery disease: a cross-sectional study in North America.

Ladapo JA, Coles A, Dolor RJ, Mark DB, Cooper L, Lee KL, Goldberg J, Shapiro MD, Hoffmann U, Douglas PS.

BMJ Open. 2017 Sep 29;7(9):e016364. doi: 10.1136/bmjopen-2017-016364.

42.

A systematic checklist approach to immunosuppression risk management: An audit of practice at two clinical neuroimmunology centers.

Mori AM, Agarwal S, Lee MWM, Rafferty M, Hardy TA, Coles A, Reddel SW, Riminton DS.

J Neuroimmunol. 2017 Nov 15;312:4-7. doi: 10.1016/j.jneuroim.2017.08.009. Epub 2017 Aug 24.

PMID:
28886954
43.

Loading of Extracellular Vesicles with Chemically Stabilized Hydrophobic siRNAs for the Treatment of Disease in the Central Nervous System.

Haraszti RA, Coles A, Aronin N, Khvorova A, Didiot MC.

Bio Protoc. 2017 Jun 20;7(20). pii: e2338. doi: 10.21769/BioProtoc.2338.

44.

Physician-assisted death should be available to people with MS - Commentary.

Coles A.

Mult Scler. 2017 Nov;23(13):1681. doi: 10.1177/1352458517730133. Epub 2017 Sep 1. No abstract available.

PMID:
28859536
45.

Prognostic Value of Coronary Artery Calcium in the PROMISE Study (Prospective Multicenter Imaging Study for Evaluation of Chest Pain).

Budoff MJ, Mayrhofer T, Ferencik M, Bittner D, Lee KL, Lu MT, Coles A, Jang J, Krishnam M, Douglas PS, Hoffmann U; PROMISE Investigators.

Circulation. 2017 Nov 21;136(21):1993-2005. doi: 10.1161/CIRCULATIONAHA.117.030578. Epub 2017 Aug 28.

46.

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.

47.

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ; CARE-MS I and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1107-1116. doi: 10.1212/WNL.0000000000004313. Epub 2017 Aug 23. Erratum in: Neurology. 2018 Apr 17;90(16):755.

48.

Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2.

Pekalski ML, García AR, Ferreira RC, Rainbow DB, Smyth DJ, Mashar M, Brady J, Savinykh N, Dopico XC, Mahmood S, Duley S, Stevens HE, Walker NM, Cutler AJ, Waldron-Lynch F, Dunger DB, Shannon-Lowe C, Coles AJ, Jones JL, Wallace C, Todd JA, Wicker LS.

JCI Insight. 2017 Aug 17;2(16). pii: 93739. doi: 10.1172/jci.insight.93739. [Epub ahead of print]

49.

Hypothyroid ataxia complicating monoclonal antibody therapy.

Badran A, Moran C, Coles AJ.

Pract Neurol. 2017 Dec;17(6):482-484. doi: 10.1136/practneurol-2017-001713. Epub 2017 Aug 4.

PMID:
28778931
50.

Use of Polycaprolactone Electrospun Nanofibers as a Coating for Poly(methyl methacrylate) Bone Cement.

Khandaker M, Riahinezhad S, Jamadagni HG, Morris TL, Coles AV, Vaughan MB.

Nanomaterials (Basel). 2017 Jul 10;7(7). pii: E175. doi: 10.3390/nano7070175.

Supplemental Content

Support Center